Shenzhen RuiXin Intelligent Medical Technology Co., Ltd. recently announced the completion of its Series D financing round worth nearly RMB100 million. This round of financing was led by Guangzhou Health Industry Investment and co-invested by Yuefu Fund. The funds will be used to drive the company's business development, accelerate overseas market expansion, and deepen the layout of an AI-driven vascular interventional surgery robot system, creating an integrated AI+robotics diagnosis and treatment platform. RuiXin Intelligent Medical focuses on precise cardiovascular diagnosis and treatment, having established an integrated intelligent diagnosis and treatment platform for cardiovascular and cerebrovascular diseases. Its core products include AngioQFA, RuiXin Fraction (CTFFR), and Intracardiac Ultrasound (ICE). Among them, AngioQFA has formed a global strategic partnership with Bluesail Medical, while RuiXin Fraction is advancing clinical applications in collaboration with iFlytek Yinglian. Looking ahead, RuiXin Intelligent Medical will continue to deepen its presence in the cardiovascular field, accelerate product commercialization, and contribute to raising the standard of cardiovascular disease diagnosis and treatment in China.